Bausch & Lomb to Market Generic Alphagan Eye Drop
The Food and Drug Administration approved
Bausch & Lomb's
(BOL)
abbreviated new drug application for a generic form of Alphagan, an eye drop designed to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension.
The company said the FDA granted marketing exclusivity for the generic medication until Sept. 20.
Brimonidine tartrate ophthalmic solution, 0.2%, is sold under the brand name Alphagan and is manufactured by
Allergan
(AGN) - Get Report
, which had tried to block the generic formulation by filing two patent-infringement lawsuits.
Bausch & Lomb's generic version of the prescription eye drop is available immediately. The company makes the product at its pharmaceuticals facility in Tampa.
Shares of Bausch & Lomb closed
New York Stock Exchange
trading Wednesday at $37.20. Allergan ended at $73.12.